Pemigatinib cohort expanded in ProTarget

We a delighted to announce that patient slots for Pemazyre (pemigatinib) have been expanded in our trial for the second time! This opportunity further expands our investigations on the efficacy and safety of pemigatinib in the tumor-agnostic setting outside the labelled indication of the drug.

Pemigatinib is a selective inhibitor of fibroblast growth factor receptor 1, 2 and 3 (FGFR1-3) – receptors that in some cases are involved in the growth and survival of cancer cells. Pemigatinib is approved for treatment of patients with locally advanced or metastatic cholangiocarcinoma harboring a fusion or rearrangement of FGFR2. In ProTarget, however, we investigate the efficacy and safety of the drug in all other tumor types in patients with advanced or metastatic cancer. Patients may be considered for inclusion if they have specific alterations in FGFR1-3 or receptor ligands, mutations in PDGFRA, PDGFRB, or PCM1-JAK2 fusions (ProTarget protocol). Patients are allocated to the treatment based on a match between the drug and the patient genomic profile evaluated and confirmed by the Danish National Molecular Tumor Board.

We initiated our investigations on pemigatinib in May 2022, and since then patient slots have been expanded twice and now includes 80 slots, which are now available to the clinical sites participating in ProTarget.

In addition to the primary endpoints within efficacy and safety, ProTarget also aims to conduct comprehensive translational research on serial liquid and tissue biopsies collected before, during and after treatment with pemigatinib. These investigations will provide better insight in potential mechanisms of resistance. Based on these efforts, we hope to provide better and broader access for targeted therapies like pemigatinib to future patients in need.

Pemigatinib is provided free of charge from Incyte together with a fee for data handling and monitoring according to ICH-GCP.